Fiorentini, F.

patient brostallicin grade cancer 12.5 mg /m cycle study level pharmacokinetic toxicity phase neutropenia treatment 12.5 course 15 mg /m 10 mg /m dose level value liter antitumor activity 3 weeks tumor analysis count plasma administration 1 patient grade 4 neutropenia infusion plasma cl dose levels effect agent antitumor activity 7 days t 1/2 relationship table trial thrombocytopenia parameter concentration hematological 10- min i.v nadir correlation blood function brostallicin pharmacokinetics range interpatient variability liters /h patient characteristics grade 3 cancer institute nausea creatinine groove liver 0.85 number research serum albumin exposure response hematological toxicity profile serum novel pharmacokinetic study pyruvate kinase parameters 1/2 phase i study baseline geroni variability coefficient 3 patients